Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
www.elrig.org
Drug Discovery 2012Manchester Central Convention Complex, UK
5th & 6th September 2012
In collaboration with
Welcome WordsWelcome to the sixth Drug Discovery meeting organized by ELRIG(European Laboratory Robotics Interest Group) in collaboration withSLAS (Society for Laboratory Automation and Screening).
Proposals for the annual ELRIG Drug Discovery meeting weredeveloped during 2005 and 2006 and led to the first meeting beingheld in Nottingham in 2007. Since that time we have had the privilegeof acting as program chairs for six annual meetings. We have seen themeeting double in size, have established the leading vendor exhibitionin the UK and have welcomed many eminent scientists includingJamie Thomson, Chris Lipinski and Philip Cohen to the meeting. Moreimportantly, the Drug Discovery meeting has become establishedwithin the meetings calendar as the major meeting place in the UK forscientists from pharma, biotech and academia interested in thechallenges of pre-candidate drug discovery.
We would now like to welcome delegates, exhibitors and speakersto the sixth annual meeting to be held once again at the ManchesterCentral exhibition centre. This meeting marks our final year as programchairs. Over the next two days a superb range of world-class Speakerswill be presenting in eight sessions covering a wide range of topicalissues for Drug Discovery including advances in Fragment Based DrugDiscovery and the complimentary biophysical and label freetechnologies applied in this field. We will explore the biology ofepigenetic enzymes and ubiquitinases as two novel families of drugtargets. We will once again discuss advances in assay developmentand screening, compound management and compound collectionenhancement, liquid handling and detection technologies. Buildingon the success of previous years we will review the application ofprimary and stem cells in discovery. In addition, the 2012 meeting willcontain two lunchtime sessions in collaboration with SLAS to explorethe growing informatics challenge of extracting knowledge fromlaboratory data.
The meeting features an extensive array of posters, snapshot talks,training, several competitions and probably the best exhibition forDrug Discovery products and services in the UK which incorporates athriving Innovation Zone for new companies promoting excitingtechnologies to the market. We also add to our conference programwhat we hope will be a challenging and entertaining Dragon’s Denevent in which innovators will present new ideas to a panel of industryleaders for discussion. Finally there will be a range of exhibitororganised meetings and training courses.
The meeting will end with a debate on the Evolving Landscape ofDrug Discovery hosted by Chris Moxham who will discuss the Lillymodel of Open Innovation and Steve Rees from AstraZeneca who willdiscuss Collaborative models for Lead Discovery.
In developing the program for this meeting ELRIG is placed at thecentre of our community with the objective of bringing togetherscientists from across the field, whether they are based in academia,the pharmaceutical or biotech industries, in order to establishrelationships to advance the science of drug discovery in the UKand Europe.
As in past years registration and attendance at the show is FREE – wecan only do this because of the support of our sponsors and exhibitors.
As we now pass the baton to Del Trezise (Essen) and Peter Simpson(AstraZeneca) the Program Chairs for the 2013 show, we would like tothank everyone who has contributed to six years of the Drug Discoveryevent but, especially Jackie Howard and Dermot Boylan of ELRIGwithout whom these meetings simply would not happen.
Drug Discovery 2013 will be back in Manchester on 3rd & 4thSeptember 2013 so please make a date in your diary!
With best regards,
Adrian Kinkaid and Stephen ReesProgram Chairs Drug Discovery 2012
About ELRIGELRIG is a Not For Profit special interest group focused on the use of automation, robotics and instrumentation in the laboratory andalso on the wider applications of laboratory automation.
Our membership consists of scientists, researchers, engineers, developers andbusiness-people who are interested in robotics, automation and associatedtechnological developments in this field.
Our primary objective is to provide an open communication forum for usersand vendors, within which members can be educated, share information andexperience and network with other members.
Our primary means of achieving this is to organise Meetings and Conferencesin which our members' experiences of automation are presented and atwhich relevant vendors exhibit their latest technology. Our aim is to provideworld-class meetings and conferences which are accessible to all.
In order to meet our open-access aims, we operate a business model in whichdelegate access to our meetings is Free of Charge. We aim to cover the cost ofstaging our events from the contributions of the exhibitors and sponsors.
About SLASThe Society for Laboratory Automation and Screening (SLAS) is aninternational community of more than 10,000 individual scientists, engineers,researchers, technologists and others from academic, government andcommercial laboratories. SLAS provides forums for education andinformation exchange to encourage the study of and advance laboratoryscience and technology for the drug discovery, agrochemical, biotechnology,chemical, clinical diagnostic, consumer product, energy, food, forensic,pharmaceutical, security and other industries.
SLAS works hard to deliver tangible educational programs and services to itsmembers. Professionals at all levels who actively invest their time and energyin their SLAS memberships often experience immeasurable returns on theirinvestments. Those who contribute as volunteers and committee membersenjoy even greater advantages.
Scientific education, practical information, professional career- building, andvaluable networking opportunities can open many doors to personal andprofessional success. Acknowledge your role in the unique field of laboratoryscience and technology. Join the only international, non-profit societydevoted exclusively to your best interests. Join SLAS today at SLAS.org.
This meeting continues to be the ideal forum for users of Flow Cytometry &Imaging Systems within drug discovery and drug development to gettogether, share expertise and innovation, discuss pitfalls, successes andfuture directions. Typical attendees will be colleagues from small-tomid-sized biotech companies, contract research organisations and globalpharmaceutical companies. The content of this free two day meeting willalso include other industrial-based themes covering the drug developmentjourney from discovery to clinical evaluation.
Chris MoxhamChris is currently an Associate VicePresident at ImClone Systems, a whollyowned subsidiary of Eli Lilly andCompany. Prior to joining ImClone, hespent 12 years at Eli Lilly and Co. in avariety of leadership roles. Most
recently he led a team that developed and launched Eli Lilly’s OpenInnovation Initiative. Chris received a B.S. in Biology from CornellUniversity and a Ph.D in Molecular and Cellular Pharmacology fromthe State University of New York at Stony Brook.
Don’t Miss the Keynote Debate:
Charter 1 at 3.45 on Day 2
The Evolving Landscape of Drug DiscoveryLilly Model of Open Innovationby Chris Moxham, Lilly
Collaborative Models for Lead Discoveryby Steve Rees, AstraZeneca
Poster Awards
Keynote Speakers
ELRIG PresentsThe SLAS Young Scientist Award
Students, graduates and post-docs are welcome to compete for the SLAS Young Scientist Award at theELRIG Drug Discovery 2012 Annual Conference and Exhibition, September 5-6, at Manchester Central, United Kingdom.
Students, graduates and post-docs are welcome to compete for the SLAS Young Scientist Award at the ELRIG Drug Discovery 2012 AnnualConference and Exhibition, September 5-6, at Manchester Central, United Kingdom.
The winner will be invited to present and participate in the Student Poster Competition at the 2nd Annual SLAS Conference and Exhibition,January 12-16, 2013 at the Gaylord Palms Resort and Convention Center in Orlando, Florida, USA. SLAS Young Scientist Award winners receive a$500 cash prize, round-trip coach airfare, shared hotel accommodations and conference registration for SLAS2013.
The winner will be invited to present and participate in the Student Poster Competition at the 2nd Annual SLAS Conference and Exhibition,January 12-16, 2013 at the Gaylord Palms Resort and Convention Center in Orlando, Florida, USA. SLAS Young Scientist Award winners receive
a $500 cash prize, roundtrip coach airfare, shared hotel accommodations and conference registration for SLAS2013.
The SLAS Young Scientist Award program is a global initiative in partnership with the following organizations:• European Laboratory Robotics Interest Group, United Kingdom• Institute of Food Technologists, United States• MipTec, Switzerland• International Society for Stem Cell Research, United States
For information regarding the ELRIG Drug Discovery 2012 SLAS Young Scientist Award,please contact Dermot Boylan, ELRIG Executive Director, at [email protected].
Steve ReesSteve Rees is Vice-President of ScreeningSciences and Sample Management atAstraZeneca with global responsibilityfor High Throughput Screening,Compound Management, the humantissue BioBank and the provision of SARbiology support to preclinical discovery
projects. Prior to joining AstraZeneca, Steve worked atGlaxoSmithKline for 24 years in various roles including that of Directorof the Screening and Compound Profiling Department. Steve hasbeen responsible for developing hit identification, compoundprofiling and compound management strategies for AstraZenencaand previously GlaxoSmithKline. Steve has led multiple internationalcollaborations and has sponsored the development andimplementation of a range of cellular assay technologies for ionchannel, GPCR and other target classes.
Steve has authored >50 scientific papers and has spoken at manyinternational symposia. Steve has been active within the Society ofLaboratory Automation and Screening (SLAS) since 2004 havingserved four years as chair of the conference committee and as a BoardMember. He is a member of the BBSRC panel of experts and is theprogram co-chair for the annual ELRIG Drug Discovery meeting.
VP Screening Sciences and Sample Management, Discovery Sciences,AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG
Lunchtime SeminarInformatics: Making Knowledge from Laboratory Data
Informatics Seminar In collaboration with SLAS- Joe Bradley, Burkhard Schaefer and Bryn Williams
Day 1 – How best to enable Externalisation of Drug DiscoveryThe last few years have seen an increasing trend to outsource screening, initially chemistry and selected
assays but increasingly entire integrated hit to lead programs with entire research areas being “virtualised”.This poses several challenges to “traditional” Pharma screening IT environments which were often not
designed to allow and coordinate inter-company screening activities.
At this session we will hear from industry experts on strategies to enable and supportthis changing landscape. This session will be an interactive, part presentation, part debate
and part open discussion on how best to achieve this.
Nick Lynch – AstraZeneca and Pistoia AllianceAnthony Carlo – Integrated Sourcing Lead, PfizerDavid Cronk – Senior Director, Biology, BioFocus
Day 2 – Knowledge at your finger tipsAt today’s session you will hear about cutting edge, open tools for use by scientists to share, find and create
information and knowledge. In order to effectively locate, interpret, link and cross reference results,information needs to be stored in a rich, standardised, computer friendly formats – these are often human
unfriendly to create and use. Now innovative, opensource tools and standards are emerging which hold thepromise to deliver these advantages in scientist friendly applications.
OpenPhacts – Dr Stefan Renner, Novartis
OpenISA – Dr Alejandra Gonzalez-Beltran , University of Oxford eResearch Centre“Community-standards for reproducible and reusable research: fundamentals and challenges”
Please note: - This informatics session is designed to be of interest and easy to follow by drug discoveryscientists of all disciplines. Talks are geared towards showing practical solutions rather than technical details.
Career Zone
Jobs Vacancies will be displayed on the Jobs Board located in the Careers Zone in the Charter Foyer – take a look.Take the opportunity of talking to the experts and get valuable Careers Advice.
If you are looking for a job, or looking for people, where better than ELRIG to network?
George James LtdGeorge James Ltd are delighted to be supporting the ELRIG DrugDiscovery Conference which has established itself as the leading
conference covering this subject hosted in the UK. During theconference we will have specialists available to provide free
45 minute advice sessions to exhibitors and delegates.
Langton HowarthLangton Howarth is a specialist recruitment consultancy working
within the Life Science, Diagnostic, Healthcare and ConsumerHealth and Beauty industries. We offer an unparalleled quality of
service and a consistent commitment towards our clients andcandidate, and aim for nothing short of excellence. Visit us at the
Careers Zone for unbiased advice about your future career move or current recruiting needs.
Visit the Vendor Lunchtime Workshops in Central 5See what others don’t – with GE Healthcare Drug Discovery Suite.
Deeper insights – better prediction of drug safety and efficacy.
Drug Discovery Suite is our portfolio of specialist technologies that allows you to achieve deeper insights atevery stage of discovery; from target identification to lead optimization. The insights into mechanisms on the
molecular as well as cellular level will help you make early predictions of drug safety and efficacyrequired to rank and select the most promising candidates to take forward.
We welcome you to our Drug Discovery Suite Seminars on the following topics:
Wednesday 5th September13.00pm – 13.40pm
Bringing Toxicology Screening into the 21st CenturyThe Power of Advanced Cell Models and High Content Analysis.
Nick Thomas, Principal Scientist, GE Healthcare Cell Technologies.
13.45pm – 14.15pmAn Innovation in Cell Analysis has Arrived – Introducing the New CytellTM Image Cytometer
Ray Ismail, Senior Scientist, GE Healthcare Cell Technologies.
Contact: Kelly Newvell on +44 (0)1622 624239 at [email protected]
Cambridge Bioscienceare sponsoring the Wi-Fithroughout the show.
The Code and Log on details are:Select: MCCC
Password: ELRIGDD12
ELRIG 2012DRAGONS DEN Join us in the Exhibition Hall at 6.30
on Day 1 where you will witness ELRIG’sanswer to DRAGONS DEN...
DragonsChris Lipinski, Pharma
Stuart Naylor, ELRIGPenny Attridge, Spark Ventures
Graeme Daniels, Cytocentrics Bioscience GmbH
Compere:Terry Wood, ELRIG Chairman
Contestants:5 Companies from within our Industry present
their New Ideas to our Panel of Dragons
Mobile App Info:Event Info in your pocket...Download the complete Drug Discovery 2012Conference schedule to your mobile device.
• View lecture and speaker profiles• View exhibitor video presentations• Rate lectures• Exhibitor interactive floor plan• In-messaging to speakers and exhibitors• Organise your day with favourites list• Share your profile as vCard and QRCode• Keep notes about lectures, speakers and exhibitors• Conference info available all year round
> For APPLE devices download at the appstore,search for EVENTFLO
> For mobile devices other than iphone and ipadplease view our 'WEBAPP' version >http://www.myeventflo.com/eventflo/eventflo.asp?pg=2&evID=1287
7 Sept 2012 in ManchesterThis half-day workshop after theELRIG conference is designed to bring scientistsworking in drug discovery and toxicology fully up todate on this hot topic. Request a 50% discountvoucher at InSphero’s stand G3 at Drug Discovery2012! Find preliminary program andregistration form here: www.insphero.com
InSpheroWorkshop“Early drug de-riskingwith 3D-cell-culturesystems”
Speaker ProgrammeSession 1, Day 1
Manchester Central Convention Complex, UK5th & 6th Sept 2012
9.00 – 9.059.05 – 9.15
Introductions andWelcomeUli Schopfer, NovartisCatherine Kettleborough, MRC
9.15 – 10.00 Session KeynoteChris Lipinski, Massachusetts University
Biologically active chemistry space and the limitsof druggability
10.00 – 10.30 Alan Harvey, Strathclyde University
Benefiting from screening natural products
10.30 – 11.00 COFFEE/ExHIBITION
11.00 – 11.30 Matthias Rottmann, Tropical Institute
Taking “one step backwards” to accelerate malariadrug discovery
11.30 – 12.00 Sheraz Gul, European ScreeningPort
Use of phenotypic assays in academic drug discovery:challenges in identifying the funding, the compounds andthe target
12.00 – 12.30 Snapshots Cisbio, EntomoPharma, Aureliabio, Brooks Life Sciences
12.30 – 2.30 LuNCH/ExHIBITION/POSTER VIEWING Lunchtime workshops
2.30 – 3.00 Justin Bryans, MRCT
Power to the People! Using crowd sourcing toenhance research
3.00 – 3.30 Ed Ainscow, GNF
Academic screening at GNF
3.30 – 4.00 Peter Simpson, AstraZeneca
Innovative Pharma - Academic Partnership models toEnhance Lead Discovery
4.00 – 5.00 POSTER PRESENTATION Charter Foyer
5.00 – 7.00 DRINkS RECEPTION Exhibition Hall
6.30 – 8.00 DRAGONS DEN Exhibition Hall
Assay Development & Screening
Speaker ProgrammeSession 2, Day 1
Manchester Central Convention Complex, UK5th & 6th Sept 2012
9.00 – 9.059.05 – 9.15
Introductions andWelcomeAndrew Leach, GSKTom Heightman, Astex
9.15 – 10.00 Session KeynoteRod Hubbard,Vernalis
Current Perspectives in Fragment Based Drug Discovery
10.00 – 10.30 David Hepworth,Pfizer
Design of a multi-purpose fragment screening library
10.30 – 11.00 COFFEE/ExHIBITION
11.00 – 11.30 Greg Osborne,Heptares
Fragment Based Approaches to GPCRs
11.30 – 12.00 Paul Wyatt,Dundee University
Dundee, Drug Discovery Unit: Using a fragment approachto partially validate novel drug discovery targets
12.00 – 12.30 Snapshots
12.30 – 2.30 LuNCH/ExHIBITION/POSTER VIEWING Lunchtime workshops
2.30 – 3.00 Chun-wa Chung,GSK
Pick and mix: optimizing the choice of biophysical andbiochemical for fragment screening
3.00 – 3.30 Rob van Montfort,ICR
Fragment-Based Screening and Structure-Based Design atICR: discovering high quality leads in cancer drug discovery
3.30 – 4.00 Andrew Woodhead,Astex
Discovery and Validation of a Novel Allosteric Binding site onthe HCV Full Length NS3/4a Enzyme
4.00 – 5.00 POSTER PRESENTATION Charter Foyer
5.00 – 7.00 DRINkS RECEPTION Exhibition Hall
6.30 – 8.00 DRAGONS DEN Exhibition Hall
Fragment Discovery for Enzyme & Membrane Targets
Speaker ProgrammeSession 3, Day 1
Manchester Central Convention Complex, UK5th & 6th Sept 2012
9.00 – 9.059.05 – 9.15
Introductions andWelcomeDel Trezise, EssenBioscienceDarren Cawkill, Pfizer
9.15 – 10.00 Session KeynoteMichael Schneider,Imperial University
Pathway Dissection in Cardiac Muscle Cell Death: MAP4K4 asa Therapeutic Target
10.00 – 10.30 James Sidaway,AstraZeneca
Stem cell derived cardiomyocytes for prediction ofdrug-induced structural cardiotoxicity
10.30 – 11.00 COFFEE/ExHIBITION
11.00 – 11.30 Rick Livesey,Cambridge University
Human stem cell models of Alzheimer's disease
11.30 – 12.00 James Bilsland,Neusentis
Generation of hESC-derived sensory neurons for PainDrug Discovery
12.00 – 12.30 Snapshots EssenBioscience, Beckman Coulter, Scottish Biomedical, InSphero
12.30 – 2.30 LuNCH/ExHIBITION/POSTER VIEWING Lunchtime workshops
2.30 – 3.00 Davide Danovi,University College London
Live cell image based chemical screens using glioma cells
3.00 – 3.30 Wolfgang Fecke,Siena Biotech
Modulating sphingosine phosphate signaling in recombinant,primary and stem cells – promises and challenges
3.30 – 4.00 Patrick Steigemann,Bayer
3D cell culture for High-Content Drug Screening
4.00 – 5.00 POSTER PRESENTATION Charter Foyer
5.00 – 7.00 DRINkS RECEPTION Exhibition Hall
6.30 – 8.00 DRAGONS DEN Exhibition Hall
Primary Cells & Stem Cells in Discovery
Speaker ProgrammeSession 4, Day 1
Manchester Central Convention Complex, UK5th & 6th Sept 2012
9.00 – 9.059.05 – 9.15
Introductions andWelcomeJason Brown, UbiquigentFrancesco Melandri, Boston BioChem
9.15 – 10.00 Session KeynoteJohn Mayer,Nottingham University
Ubiquitous ubiquitin: From reticulocyte lysates to cellphysiology and disease
10.00 – 10.30 Paul Hales,Millennium
Ubiquitin Proteasome Pathway: Assay development,platform technologies and HTS
10.30 – 11.00 COFFEE/ExHIBITION
11.00 – 11.30 Jennifer Johnston,Elan Pharma
Insight into Parkin E3 ligase activity using small molecules
11.30 – 12.00 Rob Layfield,Nottingham University
Dysfunction of ubiquitin receptors and ubiquitin-mediatedprocesses in human disease
12.00 – 12.30 Snapshots Ubiquigent, Almac
12.30 – 2.30 LuNCH/ExHIBITION/POSTER VIEWING Lunchtime workshops
2.30 – 3.00 Xavier Jacq,Mission Therapeutics
DUBs: Therapeutic challenges and opportunities
3.00 – 3.30 Benedikt Kessler,Oxford University
Novel tools for DUB inhibitor specificity profiling incancer cells
3.30 – 4.00 Mike Tatham,Dundee University
The Small Ubiquitin-like Modifiers: Established andemerging roles in diseases
4.00 – 5.00 POSTER PRESENTATION Charter Foyer
5.00 – 7.00 DRINkS RECEPTION Exhibition Hall
6.30 – 8.00 DRAGONS DEN Exhibition Hall
Ubiquitin Cascade Biology & Drug Discovery
Speaker ProgrammeSession 1, Day 2
Manchester Central Convention Complex, UK5th & 6th Sept 2012
Advances in Liquid Handling & Detection Technologies
9.00 – 9.059.05 – 9.15
Introductions andWelcomeKevin Moore, TecanDavid Cronk, BioFocus
9.15 – 10.00 Session KeynoteJohn Bradshaw,Artel
Automating Biology using Robot Scientists
10.00 – 10.30 Bev Isherwood,AstraZeneca
Understanding Error Contribution of Liquid Handling andAnalytical Equipment to Overall Assay Performance
10.30 – 11.00 COFFEE/ExHIBITION
11.00 – 11.30 Ross King,MIB
Application of High-Content Analysis for Phenotypic DrugDiscovery
11.30 – 12.00 Snapshots Tecan
12.00 – 1.45 LuNCH/ExHIBITION/POSTER VIEWING Lunchtime workshops
1.45 – 2.15 Dan Thomas,GSK
CompacT SelecT cell culture automation of humanpluripotent stem cells and their progenies
2.15 – 2.45 Melanie Leveridge,GSK
Implementation of Digital Titration to enable highresolution dose-response generation and simplifiedexperimental design
2.45 – 3.15 Yacine Laabi,I-Stem
Simplification of Lead Discovery Using RapidFire™High-Throughput Mass Spectrometry; Addressing theChallenges of Attrition and Cost Reduction
3.15 – 3.45 COFFEE BREAk
3.45 – 5.00 CLOSING kEYNOTE DEBATE:Chris Moxham, LillySteve Rees, AstraZeneca
The Evolving Landscape of Drug DiscoveryLilly Model of Open InnovationCollaborative Models for Lead Discovery
5.00 – 5.15 CLOSE OF CONFERENCE Prize Draw in Charter 1
Speaker ProgrammeSession 2, Day 2
Manchester Central Convention Complex, UK5th & 6th Sept 2012
Compound Collection Management & Enhancement
9.00 – 9.059.05 – 9.15
Introductions andWelcomeMark Wigglesworth, GSKTerry Wood, ELRIG
9.15 – 10.00 Steffen Renner,Novartis
Current thinking in compound collection enhancement
10.00 – 10.30 Andy Merritt,MRCT
MRC-T, an academic perspective on collectionenhancement and/or utilising pharmaceutical collaborationto increase collection diversity
10.30 – 11.00 COFFEE/ExHIBITION
11.00 – 11.30 Ali Tavassoli,Southampton University
Genetic selection of cyclic peptide inhibitors ofprotein-protein interactions
11.30 – 12.00 Snapshots Titian, Pro-Curo, Venomtech, Ziath Ltd
12.00 – 1.45 LuNCH/ExHIBITION/POSTER VIEWING Lunchtime workshops
1.45 – 2.15 Chris Lipinski,Massachusetts University
The issue of chemical quality in chemical biology and drugdiscovery: What should one test - a discussion
2.15 – 2.45 Kevin Cross,AstraZeneca,
Logistics of preparing a screening deck: Nanolitre assayready plates and Primary by cherry pick. Current practiceand future dispensing.
2.45 – 3.15 Zoe Blaxill,GSK
Current thinking in ensuring the quality of compoundcollections
3.15 – 3.45 COFFEE BREAk
3.45 – 5.00 CLOSING kEYNOTE DEBATE:Chris Moxham, LillySteve Rees, AstraZeneca
The Evolving Landscape of Drug DiscoveryLilly Model of Open InnovationCollaborative Models for Lead Discovery
5.00 – 5.15 CLOSE OF CONFERENCE Prize Draw in Charter 1
Speaker ProgrammeSession 3, Day 2
Manchester Central Convention Complex, UK5th & 6th Sept 2012
Epigentic Drug Discovery
9.00 – 9.059.05 – 9.15
Introductions andWelcomeDavid Wilson, GSKPaul Brennan, Oxford University
9.15 – 10.00 Session KeynoteNessa Carey,Pfizer
The challenges in turning epigenetic hope into clinical utility
10.00 – 10.30 Christopher Schofield,Oxford University
Inhibiting Epigenetic Oxygenases
10.30 – 11.00 COFFEE/ExHIBITION
11.00 – 11.30 Jason Witherington,GSK
Bromodomains: A new class of epigenetic targets ripe forsmall molecule drug discovery
11.30 – 12.00 Snapshots DiscoverX, Cerep
12.00 – 1.45 LuNCH/ExHIBITION/POSTER VIEWING Lunchtime workshops
1.45 – 2.15 Giovanna Bergamini,Cellzome
Drug Discovery based on Chemoproteomics of TargetProtein Families
2.15 – 2.45 Margaret Porter-Scott,Epizyme
Reducing histone methyl transferase biology to practice:development of physiologically relevant in vitro assays toidentify hits and successfully develop leads intocandidate molecules
2.45 – 3.15 Doris Hafenbradl,BioFocus
Epigenetic protein targets: Computational approaches andnew assay technologies for efficient hit finding against G9aand LSD1
3.15 – 3.45 COFFEE BREAk
3.45 – 5.00 CLOSING kEYNOTE DEBATE:Chris Moxham, LillySteve Rees, AstraZeneca
The Evolving Landscape of Drug DiscoveryLilly Model of Open InnovationCollaborative Models for Lead Discovery
5.00 – 5.15 CLOSE OF CONFERENCE Prize Draw in Charter 1
Speaker ProgrammeSession 4, Day 2
Manchester Central Convention Complex, UK5th & 6th Sept 2012
Biophysics & Label Free Detection Technologies
9.00 – 9.059.05 – 9.15
Introductions andWelcomeAdrian Gill, AstraZenecaLance Laing, ACEA
9.15 – 10.00 Session KeynoteManfred Auer,Edinburgh University
Application of biophysics to drug discovery anddevelopment
10.00 – 10.30 Gerhard Schuetz,Vienna University
Application of single molecule fluorescece trajectories todrug discovery and development
10.30 – 11.00 COFFEE BREAk
11.00 – 11.30 Karl Andersson,Uppsala University, Sweden
Measuring interaction complexity and time to equilibriumfor biotherapeutics in whole cell assays
11.30 – 12.00 Snapshots Corning
12.00 – 1.45 LuNCH/ExHIBITION/POSTER VIEWING Lunchtime workshops
1.45 – 2.15 Barrie Martin,Conformetrix
The application of ligand conformational preferences indrug discovery
2.15 – 2.45 Tim Fagge,GE Healthcare
Analytical Tools for affinity-based label free drug discovery –SPR and Microcalorimetry
2.45 – 3.15 Geoff Holdgate,AstraZeneca
Optical label free and other fragment supporting biophysics
3.15 – 3.45 COFFEE BREAk
3.45 – 5.00 CLOSING kEYNOTE DEBATE:Chris Moxham, LillySteve Rees, AstraZeneca
The Evolving Landscape of Drug DiscoveryLilly Model of Open InnovationCollaborative Models for Lead Discovery
5.00 – 5.15 CLOSE OF CONFERENCE Prize Draw in Charter 1
Exhibitors
4titude Ltdwww.4ti.co.uk
Essen BioScience Ltdwww.essenbioscience.com
SiLA Standardization Consortiumwww.sila-standard.org
Agilent Technologies UK Ltdwww.agilent.com/chem
Fluidxwww.2d-tubes.com
STEMCELL Technologieswww.stemcell.com
Almac Group Ltdwww.almacgroup.com
Gilson UKwww.gilsonuk.com
Stevenage Bioscience Catalystwww.stevenagecatalyst.com
AssayMetrics Limitedwww.assaymetrics.com.
Greiner Bio-Onewww.gbo.com
TAP Biosystemswww.tapbiosystems.com
Aurelia Bioscience Ltdwww.aureliabio.com
Hamamatsu Photonics UK Ltdwww.hamamatsu.co.uk
tebu-biowww.tebu-bio.com
Beckman Coulterwww.beckmancoulter.com
Hamilton Robotics Ltdwww.hamiltonrobotics.com
Tecan UK Ltdwww.tecan.com
BigNeat Ltdwww.bigneat.com
HighRes Biosolutions Ltdwww.highresbio.com
Technopath Distribution Ltdwww.techno-path.com
Biocroí Advanced Microplateswww.advancedmicroplates.com
InSphero AGwww.insphero.com
Thermo Scientific (Perbio Science UK Ltd)www.perbio.com
BioDundeewww.biodundee.co.uk
Integrated DNA Technologies BVBAwww.idtdna.com
Titian Software Ltdwww.titian.co.uk
BioScalewww.bioscale.com
IonField Systemswww.ionfieldsystems.com
TTP Labtech Ltdwww.ttplabtech.com
BioTek Instruments Ltdwww.biotek.com
Labcytewww.labcyte.com
Ziath Ltdwww.ziath.com
BMG Labtechwww.bmglabtech.com
Labman Automation Ltdwww.labman.co.uk
Zinsser Analytical GmbHwww.zinsser-analytic.net
Brooks Life Science Systemswww.brooks.com/lifescience
LGC Genomics / KBiosciencewww.lgcgenomics.com Innovation Zone:
Cambridge Biosciencewww.bioscience.co.uk
LGC Standardswww.lgcstandards.com
Biosimswww.biosims.fr
CCS Cell Culture Servicewww.cellcultureservice.com
Life Technologieswww.lifetechnologies.com
Biowakewww.swiftanalytical.com
Cellular Dynamics Internationalwww.cellulardynamics.com
Lonza Cologne GmbHwww.lonza.com
Cyclofluidic Ltdwww.cyclofluidic.co.uk
CEREP SAwww.cerep.com
Matrical Biosciencewww.matrical.com
Cryogattwww.cryogatt.co.uk
Cisbio Bioassayswww.htrf.com
Merck Milliporewww.merckmillipore.com
EntomoPharm ApSwww.entomopharm.com
CM Technologiess Oywww.c-mtechnologies.com
Miltenyi Biotec GmbHwww.miltenyibiotec.com
Flexible Lab Solutions Ltdwww.flexible-lab-solutions.co.uk
Computypewww.computype.com/en-gb
Molecular Deviceswww.MolecularDevices.com
Picodrop Ltdwww.picodrop.com
Contained Air Solutionswww.containedairsolutions.co.uk
Pall Europewww.europe.pall.com
Pro-Curo software Ltdwww.pro-curo.com
Cronus Technologies Ltdwww.cronustechnologies.co.uk
PerkinElmer LAS (UK) Ltdwww.perkinelmer.com
Sirion Biotech GmbHwww.sirion-biotech.com
CyBio Northern Europe Ltdwww.cybio-ag.com
Promega UK Ltdwww.promega.com
Snytheliswww.snythelis.com
Cytoo Cell Architectswww.cytoo.com
ProQinase GmbHwww.proqinase.com
Ubiquigentwww.ubiquigent.com
DiscoveRxwww.discoverx.com
Roche Applied Sciencewww.roche.com
Venomtech limitedwww.venomtech.co.uk
Eppendorf UKwww.eppendorf.co.uk
Scottish Biomedicalwww.scottish-biomedical.com
PicodropTM
μl Spectrophotometry made simplePPPPPμ
Poster Sponsors
MediaSponsors
SessionSponsors
DD 2012 Sponsors
Manchester Central
AZ, Alderley Park
biostorage. ABgene also provides ac
ELRIG 2012/13 Meetings
10th & 11th October 2012Pharmaceutical Flow Cytometry & Imaging
AstraZeneca R&D, Alderley Park
Meetings in 201319th March 2013
Research & InnovationTelford International Centre
19th March 2013Robotic Automation
Mitsubishi Centre, Hatfield
3 & 4th September 2013Drug Discovery 2013
Manchester Central
For more information please contact:Jackie Howard
Email: [email protected] Mob: 07879 050 555
Founding Sponsors
Products &
s
www.strobotics.com.